Alps Advisors Inc Prometheus Biosciences, Inc. Transaction History

Alps Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$103.46 - $126.29 $291,136 - $355,380	2,814 Added 9.87%	31,316 $3.36 Million
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $223,752 - $727,288	6,205 Added 27.83%	28,502 $3.14 Million
Q3 2022 Nov 14, 2022	SELL	$28.17 - $59.01 $26,874 - $56,295	-954 Reduced 4.1%	22,297 $1.32 Million
Q2 2022 Aug 11, 2022	SELL	$22.39 - $38.94 $378,480 - $658,241	-16,904 Reduced 42.1%	23,251 $656,000
Q1 2022 May 16, 2022	SELL	$30.13 - $50.0 $147,908 - $245,450	-4,909 Reduced 10.89%	40,155 $1.52 Million
Q4 2021 Feb 09, 2022	BUY	$22.28 - $39.54 $1 Million - $1.78 Million	45,064 New	45,064 $1.78 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.